(Q51322701)

3 April 2018

title

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. (English)

1 reference

3 April 2018

metabolic dysfunction–associated steatotic liver disease

main subject

type 2 diabetes

0 references

obesity

0 references

1 reference

non-alcoholic fatty liver

inferred from title

1 reference

1 reference

Ning Shao

1

1 reference

3 April 2018

Hong Yu Kuang

2

1 reference

3 April 2018

Ming Hao

3

1 reference

3 April 2018

Xin Yuan Gao

4

1 reference

3 April 2018

Wen Jian Lin

5

1 reference

3 April 2018

Wei Zou

6

1 reference

3 April 2018

publication date

1 September 2014

1 reference

3 April 2018

Diabetes - Metabolism: Research and Reviews

published in

1 reference

3 April 2018

volume

30

1 reference

3 April 2018

issue

6

1 reference

3 April 2018

page(s)

521-529

1 reference

3 April 2018

Global estimates of the prevalence of diabetes for 2010 and 2030

cites work

1 reference

Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

21 January 2018

1 reference

Obesity and type 2 diabetes

21 January 2018

1 reference

Medical Consequences of Obesity

21 January 2018

1 reference

The fatty liver and insulin resistance

21 January 2018

1 reference

Exenatide and weight loss.

21 January 2018

1 reference

Exenatide: a new promising antidiabetic agent

21 January 2018

1 reference

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

21 January 2018

1 reference

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

Exenatide: a review from pharmacology to clinical practice

21 January 2018

1 reference

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

21 January 2018

1 reference

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes

21 January 2018

1 reference

Exenatide prevents high-glucose-induced damage of retinal ganglion cells through a mitochondrial mechanism

21 January 2018

1 reference

Diabetes, oxidative stress, and antioxidants: a review

21 January 2018

1 reference

Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function

21 January 2018

1 reference

A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes

21 January 2018

1 reference

Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?

21 January 2018

1 reference

Impact of obesity in intima media thickness of carotid arteries.

21 January 2018

1 reference

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

21 January 2018

1 reference

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

21 January 2018

1 reference

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.

21 January 2018

1 reference

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

21 January 2018

1 reference

Direct effect of GLP-1 infusion on endogenous glucose production in humans

21 January 2018

1 reference

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

21 January 2018

1 reference

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

21 January 2018

1 reference

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

21 January 2018

1 reference

7 January 2021

inferred from DOI database lookup

Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus

1 reference

7 January 2021

inferred from DOI database lookup

The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/DMRR.2561

1 reference

3 April 2018

PubMed ID

24823873

1 reference

3 April 2018